Silence Therapeutics (LON:SLN) Reaches New 1-Year High at $610.00

Silence Therapeutics plc (LON:SLN) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as GBX 610 ($7.97) and last traded at GBX 605 ($7.91), with a volume of 123017 shares traded. The stock had previously closed at GBX 540 ($7.06).

Separately, Peel Hunt restated a “buy” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th.

The stock’s 50 day moving average price is GBX 381.93 and its two-hundred day moving average price is GBX 198.91. The stock has a market cap of $473.95 million and a price-to-earnings ratio of -23.91.

In related news, insider Dave Lemus purchased 4,000 shares of Silence Therapeutics stock in a transaction that occurred on Friday, October 4th. The stock was bought at an average cost of GBX 186 ($2.43) per share, for a total transaction of £7,440 ($9,721.68). Also, insider Steven Romano purchased 10,000 shares of Silence Therapeutics stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average price of GBX 193 ($2.52) per share, with a total value of £19,300 ($25,218.87).

About Silence Therapeutics (LON:SLN)

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

See Also: Blockchain

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.